

## Does Tobacco Abstinence Decrease Reward Sensitivity?

### A Human Laboratory Test

John R Hughes<sup>1</sup>, Alan J Budney<sup>2</sup>, Sharon R Muellers<sup>1</sup>, Dustin C Lee<sup>2</sup>, Peter W. Callas<sup>3</sup>, Stacey C Sigmon<sup>1</sup>, James R Fingar<sup>1</sup>, Jeff Priest<sup>3</sup>,

<sup>1</sup>Center on Health and Behavior, Department of Psychiatry, Department of Psychiatry; University of Vermont, Burlington VT; <sup>2</sup>Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH; <sup>3</sup>Department of Medical Biostatistics, University of Vermont, Burlington, VT

\*Correspondence to:

John R. Hughes, M.D

University of Vermont, Department of Psychiatry

UHC Campus, Mailstop #482 OH4

1 South Prospect Street

Burlington, VT 05401

Phone: (802) 656-1640

Fax: (802) 847-1446

Email: [john.hughes@uvm.edu](mailto:john.hughes@uvm.edu)

## 1 **Abstract**

2 **Introduction:** Animal studies report abstinence from nicotine makes rewards less  
3 rewarding; however, the results of human tests of the effects of cessation on reward  
4 sensitivity are mixed. The current study tested reward sensitivity in abstinent smokers  
5 using more rigorous methods than most prior studies.

6 **Methods:** A human laboratory study compared outcomes for 1 week prior to quitting to  
7 those during 4 weeks post-quit. The study used smokers trying to quit, objective and  
8 subjective measures, multiple measures during smoking and abstinence, and monetary  
9 rewards to increase the prevalence of abstinence. Current daily smokers (n = 211) who  
10 were trying to quit completed an operant measure of reward sensitivity and a survey of  
11 pleasure from various rewards as well as self-reports of anhedonia, delay discounting,  
12 positive affect and tobacco withdrawal twice each week. A comparison group of long-  
13 term former smokers (n = 67) also completed the tasks weekly for 4 weeks. Primary  
14 analyses were based on the 61 current smokers who abstained for all 4 weeks.

15 **Results:** Stopping smoking decreased self-reported pleasure from rewards but did not  
16 decrease reward sensitivity on the operant task. Abstinence also decreased self-  
17 reported reward frequency and increased the two anhedonia measures. However, the  
18 changes with abstinence were small for all outcomes (6-14%) and most lasted less than  
19 a week.

20 **Conclusion:** Abstinence from tobacco decreased most self-report measures of reward  
21 sensitivity; however, it did not change the objective measure. The self-report effects  
22 were small.

23 **Implications:**

24 • Animal research suggests that nicotine withdrawal decreases reward sensitivity.

25 Replication tests of this in humans have produced inconsistent results.

26 • We report what we believe is a more rigorous test

27 • We found smoking abstinence slightly decreases self-reports of reward sensitivity

28 but does not do so for behavioral measures of reward sensitivity

29

30

31

## 32 INTRODUCTION

33

34           When animals are administered nicotine chronically and this is stopped, then  
35 during withdrawal, the animals are less willing to work for rewards<sup>1-5</sup> as indicated by  
36 increased thresholds for intracranial self-stimulation during abstinence. These effects  
37 could represent an “offset” or a “withdrawal effect”<sup>6</sup>. In terms of the former, acute doses  
38 of nicotine increase the willingness of animals to work for drug and non-drug rewards<sup>7-9</sup>  
39 and this appears to be true in humans<sup>8, 10, 11</sup>; thus, when smokers quit and lose this  
40 effect, they should experience decreased reward sensitivity, simply due to the loss of  
41 the direct effects of nicotine; i.e., independent of any neural compensation.. This “offset  
42 effect” should produce a gradual unilateral change over time. On the other hand,  
43 several studies have labeled the decreased sensitivity as a “withdrawal effect. If this is  
44 correct, then deprivation should produce a transient change resulting in an inverted U  
45 shaped time course. Whether animal studies indicate an offset or withdrawal effect is  
46 unclear, in part, because few have measured reward sensitivity on multiple occasions  
47 over time

48

49           Several human studies have directly, or indirectly measured reward sensitivity  
50 with nicotine abstinence. These studies usually either measure a) a behavioral  
51 outcome in which participants either work less hard to obtain presumably rewarding  
52 stimuli (e.g. money or preferred music) or, in choice situations, allocate less responding  
53 to higher magnitude or more probable rewards or b) a self-report measure of the  
54 enjoyment or frequency of rewards or an anhedonia scale. We located 19 such trials<sup>5,</sup>  
55 <sup>10-26</sup> and two additional studies<sup>13, 16</sup> that included only self-report outcomes. Most of

56 the above studies used experimental within-participant designs (52%), dependent  
57 smokers (67%), overnight abstinence (67%), and smokers not trying to quit (85%).  
58 Overall, eight studies had positive results and 13 had null results or results that varied  
59 across dependent variables. These mixed results could be due to one or more of the  
60 following methodological decisions: a) use of smokers who are not trying to quit for  
61 good<sup>27</sup>, b) only overnight abstinence, c) small sample sizes, d) only one test during  
62 abstinence, e) confounding of measures from behavioral tasks by learning/practice  
63 effects, f) use of insensitive measures (e.g. only 1-3 questions), and g) outcomes  
64 measured well-after the usual time course for withdrawal effects<sup>28</sup>. The current study  
65 attempted to provide a more valid test of abstinence-induced reward sensitivity in  
66 humans by minimizing these problems. In addition, our study was designed to  
67 determine whether any effects of abstinence appeared to be due to the simple offset of  
68 drug effects or due to drug withdrawal. Our major hypotheses were that abstinence  
69 would a) decrease reward sensitivity on a behavioral task, and b) decrease ratings of  
70 enjoyment from rewards.

71

## 72 **METHODS**

73

74 **Study Design:** We recruited 211 smokers who were trying to quit for good to a study in  
75 which they attended two sessions/week for 5 weeks. In the first week, they smoked  
76 their usual number of cigs/day. They then quit smoking and were to remain abstinent  
77 for 4 weeks. To obtain an adequate number of continuously abstinent smokers to  
78 decrease selection bias, we used a schedule of escalating monetary incentives to

79 encourage abstinence. The two primary outcomes were performance on a behavioral  
80 task that measures reward sensitivity, and a scale that measures enjoyment from  
81 various events/activities. We also recruited a comparison group of 67 long-time former  
82 smokers to a) determine whether measures in abstinent smokers have returned to a  
83 level similar to long term abstinence and, b) whether repeated testing influences our  
84 outcomes. The study occurred at the University of Vermont and Dartmouth College and  
85 was approved by the ethics committees of both sites. The study was registered at  
86 [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT01824511).

87

88 **Participants:** Potential participants were recruited by flyers (22%), Craigslist  
89 ([www.craigslist.com](http://www.craigslist.com)) (19%), newspaper ads (18%), word-of-mouth (14%), radio ads  
90 (11%), and other sources. Generic inclusion criteria for both current and former  
91 smokers were a)  $\geq 18$  years old, b) able to read and understand English, c) no current  
92 (last year) mood or non-nicotine alcohol/drug-related psychiatric disorder, nor any  
93 neurological condition that could influence reward sensitivity; e.g. Parkinsonism<sup>29, 30</sup>, d)  
94 no current use of psychoactive medications; e.g. antidepressants or anxiolytics, e) used  
95 marijuana  $\leq 2$  times in the last month, f) agree to no use of non-cigarette tobacco, non-  
96 tobacco nicotine, marijuana, illegal drug, electronic cigarettes, or smoking cessation  
97 products during the study, and g) not currently pregnant.

98

99 The inclusion criteria for the current smoker condition were a) currently smoke  
100  $\geq 10$  cigarettes daily for  $\geq 1$  year, b) want to quit smoking for good via abrupt cessation  
101 without treatment, c) willing to quit 7-14 days from study entry and not reduce before

102 quitting, e) have carbon monoxide (CO) level  $\geq 8$  ppm at consent. We included only  
103 those wanting to quit to increase generalizability and sensitivity<sup>27</sup> and because such  
104 smokers have more withdrawal when they quit<sup>31</sup> The most common reasons for  
105 exclusion were use of a psychoactive medication, use of cannabis and too few  
106 cigarettes/day (Figure 1). Just over half of those eligible consented and entered the  
107 study (n = 211). Current smokers were generally similar to US current smokers who  
108 had recently tried to quit or were planning on quitting in gender, race, age,  
109 cigarettes/day and Fagerstrom Test for Cigarette Dependence<sup>32</sup> but were more  
110 educated (Table 1).

111

112 The inclusion criteria for the former smoker condition were a) smoked  $\geq 10$   
113 cigs/day for  $\geq 1$  years in past, b) used  $\leq 5$  cigarettes in last year, and c) have not used  
114 any non-cigarette tobacco or nicotine products in the last month. Our sample of former  
115 smokers was similar to the US average former smoker except for a higher educational  
116 level. Former smokers were similar to current smokers except they were older  
117 (Wilcoxon rank sum test  $Z = 3.4$ ,  $p < 0.001$ ) and more educated ( $\chi^2 = 49.9$ ,  $p < 0.001$ ).

118

119 **Sample Size:** Our original aim was to recruit until we obtained 70 smokers who  
120 abstained for 4 weeks. This sample size would provide  $> 90\%$  power to detect a change  
121 of 20% in scores on most of our dependent variables after abstinence, if we assumed a  
122 within-participant correlation of 0.8, which is similar to that found in our prior withdrawal  
123 studies<sup>31</sup>.

124

125           **Procedures:** We used an escalating payment schedule to increase abstinence  
126 rates. Participants attended two laboratory visits/week to provide breath samples for  
127 CO and urine samples for cotinine to verify self-reported abstinence. A CO of  $\leq 8$  ppm  
128 (Smokerlyzer, Bedfont) at both visits in the first week of instructed abstinence was  
129 required to assume initial abstinence. Although twice daily CO would be necessary to  
130 truly verify smoking, a recent study found daily or almost daily CO validation to be an  
131 adequate substitute<sup>33</sup>. For the second through fourth weeks of abstinence, we added a  
132 criteria that the urine cotinine test strip (Onescreen cotinine test, American Screening)  
133 have a value = 0 indicating cotinine < 10 ng/ml. These CO and cotinine cutoffs detect  
134 recent smoking/abstinence with high sensitivity and specificity<sup>34</sup>. We also required a  
135 negative urine cannabis dipstick result (Discover THC dipstick, American Screening)  
136 because cannabis use might mimic decreased reward sensitivity<sup>35</sup>. The monetary  
137 reward schedule was similar to that effective in our prior studies<sup>36,37</sup>. The abstinent-  
138 contingent payments began at \$16/visit and increased at each subsequent visit to a  
139 maximum of \$30/visit. In addition, participants could receive \$50 - \$100 bonuses  
140 payments for continuous abstinence. Participants abstinent for all 4 weeks received  
141 \$534. Research staff provided supportive counseling at each visit (about 5 minutes)  
142 consistent with the USPHS guidelines<sup>38</sup>.

143

144           Former smokers attended lab visits once a week for 4 weeks. Tobacco and  
145 cannabis abstinence were verified as with current smokers; however, we did not provide  
146 extra payment for abstinence. Both current smokers and former smokers also



147 received payments for attending visits and completing measures and these payments  
148 were not contingent on not smoking.

149

150 **Measures:** One primary measure was the Effort Expenditure for Rewards Task  
151 (EEfRT) that examines responding as a function of response cost, reward magnitude,  
152 and probability of reward<sup>39</sup>. The task presents participants with repeated choice tests.

153 At each test, the program presents a choice between a more difficult task in which  
154 success is rewarded with more money, or a less difficult task in which success is  
155 rewarded with less money. Participants had 3 seconds to choose which task to  
156 undertake. The harder task required 100 button presses with the non-dominant little  
157 finger in 21 seconds. The easy task required 30 presses within 7 seconds. The entire  
158 session lasted 20 minutes. The payment for each test was randomly assigned to vary  
159 from \$0.25 - \$1.05 and the probability of payment was either 12%, 50% or 88%.

160 Participants were informed on the payment and probability for each task prior to making  
161 a choice. The original EEfRT also includes a second varying probability for whether  
162 there is any payment for the test session. To keep the task easier to understand, we  
163 deleted this last probability. Reward responsivity was measured by the proportion of  
164 higher reward tasks chosen across all probabilities and then separately for the high,  
165 medium and low probability choice tests. Decreased choice of the higher reward test  
166 would indicate decreased reward sensitivity. Of the 87,787 trials, we excluded 2030  
167 (2.3%) because the participant did not make a choice of hard vs easy, or exclusively  
168 chose hard or easy throughout the session. Performance on the EEfRT has been

169 shown to be correlated with self-report measures of anhedonia and is sensitive to the  
170 effects of stimulants to increase reward seeking<sup>39-41</sup>

171

172 The other primary measure was the Rewarding Events Inventory, a self-report  
173 measure of 54 common rewards that we developed to be a more comprehensive and  
174 up-to-date measure than existing scales. The measure has excellent internal validity  
175 and test-retest reliability<sup>42</sup>. The Inventory asked participants to rate the events  
176 separately on enjoyment, with response options of “not enjoy it, enjoy it a little, enjoy it  
177 some, enjoy it a lot, extremely enjoy it”, and frequency, with response options of every  
178 day, most days, few days, one day or no days in the last week.”

179

180 To verify that participants were having withdrawal symptoms during abstinence  
181 we asked participants to rate the nine DSM-5 ([www.dsm5.org](http://www.dsm5.org)) withdrawal items from 0=  
182 not at all to 4=severe (nb, this does not include craving), using the Minnesota Nicotine  
183 Withdrawal Scale-Revised ([www.uvm.edu/~hbpl](http://www.uvm.edu/~hbpl))<sup>28, 43</sup>. The MNWS has good  
184 psychometrics<sup>28, 43</sup>. We also included measures of constructs related to reward  
185 sensitivity; i.e., anhedonia/apathy, delay discounting, and positive affect to provide  
186 convergent validity tests. One measure was the 18-item Apathy Evaluation Scale (AES)  
187 which asks about decreased pleasure or interest in rewards (e.g. “I am interested in  
188 having new experiences”)<sup>44</sup> with ratings from 1 = not at all to 4 = very true. The other  
189 was the Temporal Experience of Pleasure Scale (TEPS) that includes a 10 item interest  
190 in reward scale and an 8 item pleasure from reward scale with response options on a 6  
191 point Likert scale<sup>45</sup>. The AES and TEPS have been tested in psychiatric, drug abuse

192 and neurological patients, and have good reliability and adequate validity<sup>46-48</sup>. Positive  
193 affect was measured using the Positive and Negative Affect Scale (PANAS)<sup>49</sup>. This  
194 widely used measure has excellent reliability and validity<sup>50</sup>. We also examined delayed  
195 discounting (DD) because decreased reward sensitivity appears to be associated with  
196 decreased delay discounting<sup>51</sup>. For this measure, participants completed a delay  
197 discounting task<sup>52</sup> in which participants are given a series of hypothetical choice  
198 situations of receiving money now vs later with varying monetary values and delay  
199 periods. The amount available after the delay was always \$1000 and the range of  
200 delays was 1 day to 5 years. Across trials, a smaller, sooner reward was adjusted up or  
201 down by 50% depending on the subject's choice (smaller, sooner choices resulted in  
202 decreases; larger, delayed choices resulted in increases).

203         Results with these hypothetical choices are consistent with actual choices<sup>53</sup>.  
204 The major outcome was the k statistic which reflects the relative preference for a small,  
205 immediate reward vs. a larger delayed reward and is based on a natural log  
206 transformation of k<sup>52</sup>. A decrease in preference for the more immediate reward would  
207 assumed to indicate decreased reward sensitivity. All of the above measures were  
208 obtained at every lab visit.

209  
210         In summary, we expected that abstinence would increase withdrawal scores,  
211 decrease choice of hard response on the EEfRT, decrease enjoyment and frequency of  
212 rewards on the REI, increase anhedonia scores on the AES and TEPS, decrease  
213 positive affect, and decrease delay discounting.

214

215 **Data Analysis:** Since many smokers do not maintain abstinence during a withdrawal  
216 study, the major issue in analysis is whom to include in the analyses<sup>28</sup>. If one uses all  
217 participants, this reduces bias and generalizability resulting from examining only a  
218 subset of participants, but it requires using withdrawal scores among those who  
219 currently smoke. If one uses only those abstinent for the entire study, this avoids using  
220 smokers who are smoking but can substantially reduce the sample size and allow  
221 selection bias. Another option is to include all smokers and use abstinence status as a  
222 time-varying covariate<sup>54</sup>. This option includes all smokers but some of the withdrawal  
223 scores are based on short periods of abstinence. For the primary analysis we chose to  
224 use the 61 participants who were abstinent for the entire four weeks for four reasons: a)  
225 this is the most commonly used option in tobacco withdrawal studies<sup>31</sup>, b) several days  
226 of abstinence may be necessary to change reward sensitivity, c) our resultant sample  
227 size was still adequate for our within-participant analyses, and d) this allows a test of  
228 time pattern (i.e., whether the results appear to be due to simple drug offset or to drug  
229 withdrawal) that is not influenced by different participants at different timepoints. We  
230 also undertook two sensitivity tests using a) the larger sample (n= 104) of participants  
231 abstinent during the first week when abstinence symptoms typically peak, and b) all 211  
232 participants with abstinence status as a time-varying covariate.

233

234 Our major analyses were based on within-participant ANOVAs. We used mixed  
235 linear modeling to conduct longitudinal analyses of outcomes, including both restricted  
236 maximum likelihood of fixed effects with a compound symmetric covariance matrix, and  
237 random effects with an unstructured covariance matrix. All analyses were conducted

238 using SAS 9.4 software (SAS Institute, Cary, NC) and statistical significance across all  
239 tests was defined as  $p < .05$  (2-tailed). Our pre-specified major test among current  
240 smokers was a comparison of the mean EEfRT and REI enjoyment scores during the  
241 smoking-as-usual period vs the mean during the entire abstinence period. We also  
242 specifically tested for an inverted U shape pattern in abstinence for all outcomes; i.e.,  
243 whether any outcomes had any initial increase/decrease or during abstinence which  
244 abated over time during the abstinence period via an ANOVA confined to the  
245 abstinence period. We also used paired t tests to compare peak baseline score and  
246 peak score during abstinence using the highest score as peak for those measures  
247 expected to increase with abstinence and lowest score for those expected to decrease.  
248 We next compared results between former smokers and newly abstinent smokers to  
249 see if the recent abstainers had returned to the level of long-term former smokers. To  
250 do this, we tested whether the results at the 3<sup>rd</sup> and 4<sup>th</sup> visits among abstainers differed  
251 from the results from the 3<sup>rd</sup> and 4<sup>th</sup> visit results among long-term former smokers, again  
252 with an ANOVA.

253

## 254 **RESULTS**

255

256 **Initial Analyses:** About half ( $n=104$ , 52%) of participants were abstinent for  $\geq 1$  week  
257 but this decreased to about a fourth ( $n = 61$ , 29%) abstinent for all 4 weeks (Figure 1;  
258 Appendix, Figure 1). As in most clinical studies, those who were able to abstain longer  
259 (i.e., for 4 weeks) were older (Wilcoxon rank sum test  $Z = 2.0$ ,  $p = .05$ ), more educated  
260 (Fisher's Exact Test,  $p = .004$ ) and smoked fewer cigs/day (Wilcoxon rank sum test  $Z =$

261 3.0,  $p = .003$ ) than those who were not able to do so. Among the 61 fully abstinent  
262 participants, the two baseline values did not differ from each other for any outcome,  
263 indicating they represent stable baseline scores. The mean score for the MNWS score  
264 during abstinence was substantially greater than the mean score during smoking  
265 (+43%) indicating these 61 participants were in withdrawal during the abstinence period  
266 ( $F=64.8$ ,  $p < 0.001$ ). For most measures, the scores for the four tests among long-  
267 abstinent smokers found little change with repeated testing ( $< 2.5\%$  change from one  
268 time point to the next); however, preference for the harder task on the EEfRT increased  
269 overtime (6.7% increase between tests). There were no significant differences  
270 between the 3<sup>rd</sup> and 4<sup>th</sup> visits for long-term former smokers.

271  
272 **Main Analyses:** Contrary to our hypothesis, the mean proportion of choices that were  
273 for the higher-reward task on the EEfRT task during the abstinence period was greater,  
274 not smaller, than the mean proportion during the smoking period ( $F=40.4$ ,  $p < 0.001$ ;  
275 see Table 2, Figures 2 and 3). When we looked at results at each of the three  
276 probability of reward settings on the EEfRT, one showed no change and the other two  
277 showed an increase, not a decrease; at probability =0.12,  $F=0.7$ ,  $p =0.39$ ; at  
278 probability=0.50,  $F= 52.2$ , and  $p <0.001$ ; at probability=0.88,  $F=82.3$ ,  $p <0.001$ . In  
279 contrast, consistent with our major hypothesis, abstinence decreased the rated  
280 enjoyment from rewards on the REI,  $F=133.1$ ,  $p <0.001$ . Also, consistent with our  
281 hypotheses, abstinence decreased the frequency of rewarding events, ( $F=58.4$ ,  $p <$   
282  $0.001$ ) and the delay discounting outcome, ( $F=22.5$ ,  $p <0.0010$ ) and increased scores on  
283 the AES,  $F=11.4$ ,  $p=0.001$ , and TEPS scales, ( $F=5.5$ ,  $p=0.02$ ), However, the

284 magnitudes of change for both our primary and secondary outcomes were small (6-  
285 14%, see Table 2 and Figures 2 and 3). Using the mean score across all abstinence  
286 measures as the dependent variable could have obscured a change that occurred on  
287 only one or two days during abstinence. To test this, we reran the analyses comparing  
288 the peak value during abstinence vs the peak value during smoking. The results were  
289 very similar (Appendix Table 1).

290

291 **Time Course:** True withdrawal symptoms exhibit an inverted U time course; to test this  
292 we examined whether, among the five outcomes that showed the hypothesized initial  
293 change with abstinence (REI enjoyment, REI frequency, DD, TEPS and AES), whether  
294 these changes scores then decreased over time (i.e., we compared scores in week 1 vs  
295 the average across weeks 2-4). This was true for the REI enjoyment ( $t = 2.1$ ,  $p = 0.04$ ),  
296 REI frequency ( $t = -3.2$ ,  $p = 0.002$ ) and DD ( $t = -2.4$ ,  $p = .02$ ) outcomes but not for the  
297 AES or TEPS scores. Figures 2 and 3 illustrate the magnitude of these results

298

299 **Former Smokers:** After adjusting for subject characteristics that differed between  
300 former and current smokers, recently abstinent smokers had higher MNWS scores, ( $F =$   
301  $30.1$ ,  $p < 0.001$ ), and AES scores, ( $F = 4.4$ ,  $p = .04$ ); but lower positive affect scores, ( $F$   
302  $= 8.5$ ,  $p < 0.004$ ), than former smokers. Abstinent smokers also had lower REI  
303 enjoyment scores (Wilcoxon rank sum test  $Z = -2.1$ ,  $p = .03$ ), although we could not  
304 meet ANOVA assumptions for including baseline differences in this particular test.  
305 Figures 2 and 3 illustrate the magnitude of differences.

306

307 **Sensitivity Analyses:** We reran the major analysis; i.e., a comparison of mean  
308 smoking vs mean abstinence score for the EEfRT and REI enjoyment but only  
309 examined results from the first week of abstinence and included all participants  
310 abstinent during the first week (n = 104). We also reran analyses using all participants  
311 (n = 211) and using abstinent state as a time-varying covariate. In both analyses, the  
312 results were very similar to that for the 61 long-abstinent smokers. The results of these  
313 analyses are in Appendix Tables 2 and 3. .

314

## 315 **DISCUSSION**

316 Cigarette abstinence decreased self-reports of pleasure from and frequency of  
317 rewards on a reward inventory, and increased scores on the two anhedonia scales.  
318 That all four of these changed in the hypothesized direction suggests convergent  
319 validity of results. On the other hand, the magnitude of change in these outcomes was  
320 only 4-8%. Among the 21 prior studies of the effect of abstinence on reward sensitivity,  
321 6 examined change in self-reports, among these, 3 found anhedonia increased but only  
322 one reported the magnitude of change (+19% estimated from graph)<sup>16</sup> and this was  
323 probably the study with the highest internal and external validity.

324 Abstinence did not decrease reward sensitivity in the behavioral test of reward  
325 sensitivity - the EEfRT. Among the 15 prior studies that examined a behavioral task of  
326 reward sensitivity, 7 (47%) reported abstinence decreased sensitivity. Among the six  
327 studies that reported magnitude of effects, the median decrease was only 2.5%.  
328 However, the study that was the most rigorous test and used a validated behavioral task  
329 found abstinence completely eliminated preference for the higher magnitude reward<sup>5</sup>.



330 One possible reason we failed to find an effect on EEfRT on the behavioral task was  
331 that scores on the EEfRT appeared to increase over time, suggesting a learning effect  
332 that may have obscured any decline due to abstinence. Prior studies have not  
333 measured the EEfRT repeatedly over time; thus, whether learning effects are common  
334 with EEfRT requires further testing. Another possible reason for different outcomes in  
335 self-report vs behavioral task outcomes is that they are measuring two different aspects  
336 of reward sensitivity<sup>55</sup>; i.e., the former is measuring hedonic response and the latter  
337 motivation to pursue rewards.

338 In terms of other secondary outcomes, if abstinence decreases reward  
339 sensitivity, then this should decrease delay discounting<sup>56</sup> which is what we found, albeit  
340 the magnitude of this effect was small. Across the ten prior studies of the effect of initial  
341 abstinence on delay discounting, two found abstinence decreased DD<sup>52, 57</sup>, four found  
342 it produced no change<sup>33, 58-60</sup> and four found abstinence increased DD<sup>61-64</sup>. Our  
343 reading of these studies does not suggest a clear reason for these heterogeneous  
344 results. It may be because the DD task and how its results are calculated differs across  
345 studies. Also, studies that found abstinence increased DD, interpreted this as indicating  
346 abstinence increases impulsivity, which is consistent with other studies<sup>65</sup>. Thus, it may  
347 be that abstinence has two opposing effects on DD tasks; i.e., it decreases reward  
348 sensitivity but also increases impulsivity.

349 One possible limitation of our results is that our main analysis used only the 30%  
350 of our participants who were abstinent for the desired 4 week period; however, tests  
351 using a larger sample of those initially abstinent and using all participants obtained  
352 similar results. Also, we did not conduct a randomized trial of abstinent vs non-

353 abstinent conditions. Instead we used a pre-post design in which participants served as  
354 their own control. Although such non-randomized designs can have methodological  
355 problems, in fact, most studies of tobacco withdrawal have used pre vs post designs  
356 and have provided very replicable data. We did not include several measures of reward  
357 sensitivity such as neuroimaging<sup>66</sup> or response to hedonic stimuli<sup>19, 67</sup> that tap other  
358 aspects of reward sensitivity; e.g. reward anticipation or reward learning. Our  
359 participants were more educated and more nicotine dependent than the average US  
360 smoker and had no use of psychoactive drugs or current psychiatric disorder; this may  
361 decrease the external validity of our study. The influence of abstinence may differ by  
362 psychiatric status<sup>5</sup>; however, we did not collect information on past or current psychiatric  
363 status. Our sample size for analysis might be thought of as small; however, our data  
364 analysis was based on a within-participant comparison with multiple pre and post-  
365 cessation values.

366 To our knowledge, this was the first use of the EEfRT to examine the effects of  
367 smoking abstinence. Several studies have found EEfRT can detect reward sensitivity  
368 changes with other drugs<sup>39, 41, 68-71</sup>. Our first post-cessation EEfRT measurement did  
369 not occur until 3-4 days after cessation. Some prior studies suggest the effect of  
370 abstinence on reward sensitivity occurs immediately after cessation<sup>5</sup>; thus we could  
371 have missed a short-lived effect. Although one could believe such a “fleeting” effect  
372 would not be clinically important, this may not be the case because over half of all  
373 relapses occur in the first 3 days<sup>72</sup>. Finally, our contingency program to increase  
374 abstinence relied on testing at only 2 visits/week and thus, some smoking could have  
375 occurred between the visits and this decreased the sensitivity of our test. On the other

376 hand, the scores on the MNWS increased substantially indicating participants were in  
377 withdrawal during the last 4 weeks of the study.

378

379 Compared to the prior studies of the effect of tobacco abstinence on reward  
380 sensitivity, the current study had the following methodological assets: a) use of  
381 smokers who are trying to quit for good, b) longer period of abstinence that included the  
382 typical time periods for tobacco withdrawal, c), a sufficient time period to detect if effects  
383 due to withdrawal or simple offset of direct effects, d) multiple measures during  
384 smoking and abstinence periods, e) use of both objective and subjective measures, f)  
385 multiple measures to allow test of convergent validity, g) abstinence verification on  
386 multiple occasions, and h) experimental induction of abstinence.<sup>28</sup>

387 In summary, our self-report results suggest abstinence induces a small decrease  
388 in reward sensitivity, but our behavioral task did not confirm this. Animal studies clearly  
389 predict that smoking cessation should decrease reward sensitivity (see above). We  
390 believe the small decrease in reward sensitivity we observed in a subset of the  
391 measures is a weak confirmation of the applicability of animal data to smoking cessation  
392 in humans. Given the heterogeneity of prior results on whether smoking abstinence  
393 decreases reward sensitivity and the limitations of our own methods, further studies of  
394 abstinence-induced decreased reward sensitivity using other behavioral tasks such as  
395 the Progressive Ratio task<sup>10</sup> or the Signal Detection Task<sup>73</sup> that may be more sensitive  
396 or reliable, concomitant with self-report measures, are needed to further clarify the  
397 importance of reward sensitivity to smoking cessation.

398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433

**Funding:** This study was supported by a grant from the US National Institutes of Health (1 R01 DA-031687).

**Acknowledgements:** We thank Jean Francois Etter for help in designing the study and in conducting studies developing the Rewarding Events Inventory. We thank Michael Treadway for sharing his EEfRT task with us. We also thanks Bonita Basnyat, Erin Kretzer, Doris Gasangwa, Grey Norton, Stanley See, Hao Yani for assistance in conducting the study and Jessie McNabb for help in preparing the manuscript. .

**Declaration of Interests:** JRH has received consulting fees from companies that develop or market products for smoking cessation or harm reduction and from non-profit companies that engage in tobacco control. Other authors have nothing to disclose.

434 Table 1.

435 Comparison of study sample with a population based sample

436

437

	Current Study			
	Current Smokers ( <i>n</i> = 211)	Former Smokers ( <i>n</i> = 67)	US Current Smokers with Recent Quit Attempt <sup>a</sup>	US Former Smokers <sup>a</sup>
% Women	45%	46%	46%	46%
% White/Non-Latino	86%	85%	74%	74%
Age ( <i>M</i> ± <i>SD</i> )	40 ± 15	47±16	40	40
% Some college or more	67%	93%	46%	57%
% Employed	62%	69%	-	-
Cigarettes per day ( <i>M</i> ± <i>SD</i> )	19 ± 8	-	16	-
FTCD Total ( <i>M</i> ± <i>SD</i> )	5.0 ± 2.1	-	4.4	-

438 <sup>a</sup>Based on 2007 National Health Interview Survey <sup>74</sup>, National Epidemiological Survey  
439 on Alcohol and Related Conditions <sup>75</sup>, and Fagerstrom & Furburg <sup>76</sup>

440 *M*= mean, *SD*= standard deviation, FTCD= Fagerstrom Test for Cigarette Dependence

441 <sup>32</sup>

442

443

444

445 Table 2. Baseline vs. Abstinent Scores in Participants Abstinent for Four Weeks (n=61)  
 446 and Among Positive Results, Whether Time Course Was Consistent With That of a  
 447 Withdrawal Symptom

448

449

Mean Baseline vs. Mean Abstinent					
Variable (range)	Baseline	Abstinent	Absolute Change	Percent Change	Withdrawal Time Pattern <sup>b</sup>
EEfRT (0-1)	0.51	0.58 <sup>***a</sup>	+0.07	+14%	No
REI Enjoy (1-5)	3.7	3.5 <sup>***</sup>	-0.2	-5%	Yes
REI Frequency (1-5)	2.6	2.4 <sup>***</sup>	-0.2	-8%	Yes
AES (18-72)	29.2	30.9 <sup>***</sup>	+1.7	+6%	No
TEPS (18-108)	41.7	43.5 <sup>*</sup>	+1.8	+4%	
PANAS PA (10-50)	33.8	33.3	-0.5	-2%	
Delay discounting (ln k)	-6.4	-6.8 <sup>***</sup>	+0.4	+6%	Yes

450

<sup>a</sup>Note opposite to hypothesized change

451

\* p < .05

452

\*\* p < .01

453

\*\*\* p < .001

454

AES = Apathy Evaluation Scale, EEfRT = Effort Expenditure for Rewards Task, K = test statistic for degree of discounting, ln = natural log, NA = Negative Affect, PA = Positive Affect, PANAS = Positive and Negative Affect Scale, REI = Rewarding Events Inventory, TEPS = Temporal Experience of Pleasure Scale

455

<sup>b</sup>Withdrawal pattern defined as first post-cessation value greater than remaining post-cessation values

456

457

458

459

460

461

462

463

464

465

466

467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501

## Reference List

- (1) Dagher A, Bleicher C, Aston JAD, Gunn RN, Clarke PBS, Cumming P. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. *Synapse* 2001;42:48-53.
- (2) Epping-Jordan M, Watkins S, Koob G, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. *Nature* 1998;393:76-79.
- (3) Melis M, Spiga S, Diana M. The dopamine hypothesis of drug addiction: Hypodopaminergic state. *International Review of Neurobiology* 2005;63:101-154.
- (4) Koob GF, LeMoal M. Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology* 2001;24:97-129.
- (5) Pergadia M, Der-Avakian A, D'Souza M et al. Association between nicotine withdrawal and reward responsiveness in humans and rats. *JAMA Psychiatry* 2014;71:1238-1245.
- (6) Hughes JR. Distinguishing withdrawal relief and direct effects of smoking. *Psychopharm* 1991;104:409-410.
- (7) Chaudhri N, Caggiula A, Donny E, Palmatier M, Lui X, Sved A. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. *Psychopharm* 2006;184:353-366.
- (8) Barr R, Pizzagalli D, Culhane M, Goff D, Evins A. A single dose of nicotine enhances reward responsiveness in nonsmokers: Implications for development of dependence. *Biol Psychiatr* 2008;63:1061-1065.
- (9) Kenny P, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. *Neuropsychopharmacology* 2006;31:1203-1211.
- (10) Perkins KA, Karelitz J. Reinforcement enhancing effects of nicotine via smoking. *Psychopharm* 2013;228:479-486.
- (11) Perkins K, Karelitz J. Influence of reinforcer magnitude and nicotine amount on smoking's acute reinforcement enhancing effects. *Drug Alcohol Depend* 2013;133:167-171.
- (12) Al-Adawi S, Powell J. The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. *Addiction* 1997;92:1773-1782.
- (13) Snuggs S, Hajek P. Responsiveness to reward following cessation of smoking. *Psychopharm* 2013;225:869-873.

- 502 (14) Attwood AS, Penton-Voak IS, Munafo MR. Effects of acute nicotine  
503 administration on ratings of attractiveness of facial cues. *Nicotine & Tobacco*  
504 *Research* 2009;11(1):44-48.
- 505 (15) Buhler M, Vollstadt-Klein S, Kobiella A et al. Nicotine dependence is  
506 characterized by disordered reward processing in a network driving motivation.  
507 *Biol Psychiatr* 2009;67:745-752.
- 508 (16) Cook J, Piper M, Leventhal A, Schlam T, Fiore M, Baker T. Anhedonia as a  
509 component of the tobacco withdrawal syndrome. *J Abn Psychol* 2015;124:215-  
510 225.
- 511 (17) Dawkins L, Powell J, Pickering A, Powell J, West R. Patterns of change in  
512 withdrawal symptoms, desire to smoke, reward motivation and response  
513 inhibition across 3 months of smoking abstinence. *Addiction* 2009;104:850-858.
- 514 (18) Dawkins L, Powell J, West R, Powell J, Pickering A. A double-blind placebo  
515 controlled experimental study of nicotine: I. Effects on incentive motivation.  
516 *Psychopharm* 2006;189:355-367.
- 517 (19) Dawkins L, Acaster S, Powell J. The effects of smoking and abstinence on  
518 experience of happiness and sadness in response to positively valenced,  
519 negatively valenced, and neutral film clips. *Addict Behav* 2007;32:425-431.
- 520 (20) Kalamboka N, Remington B, Glautier S. Nicotine withdrawal and reward  
521 responsivity in a card-sorting task. *Psychopharm* 2009;204:155-163.
- 522 (21) Lawn W, Freeman TP, Hindocha C et al. The effects of nicotine dependence  
523 and acute abstinence on the processing of drug and non-drug rewards.  
524 *Psychopharm* 2015;232:2503-2517.
- 525 (22) Leventhal AM, Munafo M, Tidey J et al. Anhedonia predicts altered processing  
526 of happy faces in abstinent cigarette smokers. *Psychopharm* 2012;222:343-  
527 351.
- 528 (23) Perkins KA, Karelitz JL. Sensory reinforcement-enhancing effects of nicotine  
529 via smoking. *Experimental Clinical Psychopharmacology* 2014;22:511-516.
- 530 (24) Perkins K, Grottenthaler A, Wilson A. Lack of reinforcement enhancing effects  
531 of nicotine in non-dependent smokers. *Psychopharm* 2009;205:635-645.
- 532 (25) Powell J, Dawkins L, West R, Powell J, Pickering A. Relapse to smoking during  
533 unaided cessation: clinical, cognitive and motivational predictors. *Psychopharm*  
534 2009;212:537-549.
- 535 (26) Powell J, Pickering A, Dawkins L, West R, Powell J. Cognitive and  
536 psychological correlates of smoking abstinence, and predictors of successful  
537 cessation. *Addict Behav* 2004;29:1407-1426.




- 538 (27) Perkins K, Lerman C, Stitzer M et al. Development of procedures for early  
539 screening of smoking cessation medications in humans. *Nature* 2008;84:216-  
540 221.
- 541 (28) Hughes JR. Measurement of the effects of abstinence from tobacco. A  
542 qualitative review. *Psychol Addict Behav* 2007;21:127-137.
- 543 (29) Duffy J. Apathy in neurologic disorders. *Current Psychiatry Reports*  
544 2000;2:434-439.
- 545 (30) Starkstein S, Leentjens A. The nosological position of apathy in clinical  
546 practice. *Journal of Neurology, Neurosurgery, and Psychiatry* 2008;79:1088-  
547 1092.
- 548 (31) Hughes JR. The effects of abstinence from tobacco: Valid symptoms and time  
549 course. *Nicotine & Tobacco Research* 2007;9:315-327.
- 550 (32) Fagerstrom K. Determinants of tobacco use and renaming the FTND to the  
551 Fagerstrom Test for Cigarette Dependence. *Nicotine & Tobacco Research*  
552 2012;14:75-78.
- 553 (33) Yoon J, Higgins S, Bradstreet M, Badger G, Thomas C. Changes in the relative  
554 reinforcing effects of cigarette smoking as a function of initial abstinence.  
555 *Psychopharm* 2009;205:305-318.
- 556 (34) SRNT Subcommittee on Biochemical Verification. Biochemical verification of  
557 tobacco use and cessation. *Nicotine & Tobacco Research* 2002;4:149-159.
- 558 (35) Cherek DR, Lane SD, Dougherty DM. Possible amotivational effects following  
559 marijuana smoking under laboratory conditions. *Experimental and Clinical*  
560 *Psychopharmacology* 2002;10:26-38.
- 561 (36) Reimann E, Badger G, Heil S, Higgins S. A contingency-management  
562 intervention to promote initial smoking cessation among opioid-maintained  
563 patients. *Exp Clin Psychopharm* 2010;18:37-50.
- 564 (37) Heil SH, Higgins S, Bernstein I et al. Effects of voucher based incentives on  
565 abstinence from cigarette smoking and fetal growth among pregnant women.  
566 *Addiction* 2009;103:1009-1018.
- 567 (38) Fiore M, Jaen C, Baker T et al. *Treating Tobacco Use and Dependence:*  
568 *Clinical Practice Guideline*. Washington, DC: US Public Health and Human  
569 Services; 2008.
- 570 (39) Treadway M, Buckholtz J, Schwartzman A, Lambert W, Zald D. Worth the  
571 'EEfRT'? The effort expenditure for rewards task as an objective measure of  
572 motivation and anhedonia. *PLoS One* 2009;4:e6598.

- 573 (40) Wardle MC, Treadway MT, de wit H. Caffeine increases psychomotor  
574 performance on the effort expenditure for rewards task. *Pharmacol Biochem*  
575 *Behav* 2012;102:526-531.
- 576 (41) Wardle M, Treadway M, Mayo L, Zald D, de Wit H. Amping up effort: Effects of  
577 *d*-amphetamine on human effort-based decision-making. *The Journal of*  
578 *Neuroscience* 2011;31:16597-16602.
- 579 (42) Hughes JR, Etter JF, Callas P, Budney A, Fingar J, Sigmon S. A self-report  
580 scale to measure the effect of nicotine on rewarding events. 2014 Feb 7; 2014.
- 581 (43) Shiffman S, West RJ, Gilbert DG. Recommendation for the assessment of  
582 tobacco craving and withdrawal in smoking cessation trials. *Nicotine & Tobacco*  
583 *Research* 2004;6:599-614.
- 584 (44) Marin R, Biedrzycki R, Firinciogullari S. Reliability and validity of the Apathy  
585 Evaluation Scale. *Psychiatr Res* 1991;38:143-162.
- 586 (45) Gard D, Gard J, Kring A, John O. Anticipatory and consummatory components  
587 of the experience of pleasure: A scale development study. *Journal of Research*  
588 *in Personality* 2006;40:1086-1102.
- 589 (46) D'haenen H. Measurement of anhedonia. *European Psychiatry* 1996;11:335-  
590 343.
- 591 (47) Horan W, Kring A, Blanchard J. Anhedonia in schizophrenia: A review of  
592 assessment strategies. *Schizophr Bull* 2006;32:259-273.
- 593 (48) Leentjens A, Dujardin K, Marsh L et al. Apathy and anhedonia rating scales in  
594 Parkinson's Disease: Critique and recommendations. *Movement Disorders*  
595 2008;23:2004-2014.
- 596 (49) Watson D, Clark L, Tellegen A. Development and validation of brief measures  
597 of positive and negative affect: The PANAS scales. *Journal of Personality and*  
598 *Social Psychology* 1988;54:1063-1070.
- 599 (50) McDowell I. Measures of self-perceived well-being. *J Psychosom Res*  
600 2010;69:69-79.
- 601 (51) Lempert KM, Pizzagalli DA. Delay discounting and future-directed thinking in  
602 anhedonic individuals. *Journal of Behavior Therapy and Experimental*  
603 *Psychiatry* 2010;41:258-264.
- 604 (52) Yi R, Landes R. Temporal and probability discounting by cigarette smokers  
605 following acute smoking abstinence. *Nicotine & Tobacco Research*  
606 2012;14:547-558.

- 607 (53) Madden G, Raiff B, Lagorio C et al. Delay discounting of potentially real and  
608 hypothetical rewards: II. Between- and within-subject comparisons. *Exp Clin*  
609 *Psychopharm* 2004;12:251-261.
- 610 (54) Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal  
611 dynamics: I. Abstinence distress in lapsers and abstainers. *J Abn Psychol*  
612 2003;112:3-13.
- 613 (55) Strauss G, Gold J. A new perspective on anhedonia in schizophrenia. *Am J*  
614 *Psychiatr* 2012;169:364-373.
- 615 (56) National Institute on Drug Abuse, National Institutes of Health, The Robert  
616 Wood Johnson Foundation, National Cancer Institute, Office on Smoking and  
617 Health, Centers for Disease Control and Prevention. Addicted to nicotine: A  
618 national research forum. *Nicotine & Tobacco Research* 1999;Suppl 2:S1-215.
- 619 (57) Ashare RL, Jr. HLW. Effects of smoking abstinence on impulsive behavior  
620 among smokers high and low in ADHD-like symptoms. *Psychopharm*  
621 2012;219:537-547.
- 622 (58) Roewer I, Wiehler A, Peters J. Nicotine deprivation, temporal discounting and  
623 choice consistency in heavy smokers. *J Exp Anal Behav* 2015;103:62-76.
- 624 (59) Mitchell S. Effects of short-term nicotine deprivation on decision-making: Delay,  
625 uncertainty and effort discounting. *Nicotine & Tobacco Research* 2004;6:819-  
626 828.
- 627 (60) Ashare RL, Kable JW. Sex differences in time perception during smoking  
628 abstinence. *Nicotine and Tobacco Research* 2015;17:449-454.
- 629 (61) Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. Delay discounting and  
630 the behavioural economics of cigarette purchases in smokers: The effects of  
631 nicotine deprivation. *Psychopharm* 2006;186:255-263.
- 632 (62) Yi R, Johnson M, Giordano L, Landes R, Badger G, Bickel W. The effects of  
633 reduced cigarette smoking on discounting future rewards: An initial evaluation.  
634 *The Psychological Record* 2008;58:163-174.
- 635 (63) Searcy GD. Short-term nicotine abstinence and decision making. Kalamazoo,  
636 MI: Western Michigan University; 2012.
- 637 (64) Heckman BW. Self-control depletion and nicotine deprivation as precipitants of  
638 smoking cessation failure: A human laboratory model. Tampa, FL: University of  
639 South Florida; 2015.
- 640 (65) Hughes JR, Dash.M., Callas PW. Is impulsivity a symptom of initial tobacco  
641 withdrawal? A meta-analysis and systematic review. *Nicotine & Tobacco*  
642 *Research* 2015;17:503-509.


- 643 (66) Sweitzer M, Geier C, Joel D et al. Dissociated effects of anticipating smoking  
644 versus monetary reward in the caudate as a function of smoking abstinence.  
645 *Biol Psychiatr* 2014;76:681-688.
- 646 (67) Bonn-Miller MO, Moos RH, Boden MT, Long WR, Kimerling R, Trafton JA. The  
647 influence of posttraumatic stress disorder on cannabis quit success. *Am J Drug*  
648 *Alcohol Abuse* 2015;41(4):339-344.
- 649 (68) Treadway M, Bossaller N, Shelton R, Zald D. Effort-based decision-making in  
650 major depressive disorder: A translational model of motivational anhedonia. *J*  
651 *Abn Psychol* 2012;121:553-558.
- 652 (69) McCarthy JM, Treadway M, Blanchard J. Motivation and effort in individuals  
653 with social anhedonia. *Schizophrenia Research* 2015;165:70-75.
- 654 (70) Treadway M, Peters A, Zald D, Park S. Impaired effort allocation in patients  
655 with schizophrenia. *Schizophrenia Research* 2015;161:382-385.
- 656 (71) Barch DM, Treadway M. Effort, anhedonia, and function in schizophrenia:  
657 Reduced effort allocation predicts amotivation and functional impairment. *J Abn*  
658 *Psychol* 2014;123:387-397.
- 659 (72) Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term  
660 abstinence among untreated smokers. *Addiction* 2004;99:29-38.
- 661 (73) Pizzagalli D, Jahn A, O'Shea J. Toward an objective characterization of an  
662 anhedonic phenotype: A signal-detection approach. *Biol Psychiatr*  
663 2005;57:319-327.
- 664 (74) Hughes JR, Callas PW. Data to assess the generalizability of samples from  
665 studies of adult smokers. *Nicotine & Tobacco Research* 2010;12:73-76.
- 666 (75) Hasin DS, Grant BF. The National Epidemiologic Survey on Alcohol and  
667 Related Conditions (NESARC) waves 1 and 2: Review and summary of  
668 findings. *Social Psychiatry of Psychiatric Epidemiology* 2015;50:1609-1640.
- 669 (76) Fagerstrom K, Furberg H. A comparison of the Fagerstrom Test for Nicotine  
670 Dependence and smoking prevalence across countries. *Addiction*  
671 2008;103:841-845.  
672  
673  
674  
675

Figure 1. Participant flowchart




All percents are of the number in box above. Rx = prescription

Figure 2. Time course for selected outcomes.



Solid line = current smokers. Dotted line = former smokers. AES = Apathy Evaluation Scale, MNWS = Minnesota Nicotine Withdrawal Scale, TEPS = Temporal Evaluation of Pleasure Scale

Figure 3. Time course for selected outcomes



Solid line = current smokers. Dotted line = former smokers. PANAS = Positive Affect and Negative Affect Scale, REI = Rewarding Events Inventory